Zota Health Care Shares Rated New 'Buy' At Nirmal Bang — Check Target Price, Potential Upside And More

Davaindia contributes ~64% of Zota’s FY25 revenue and remains the company’s most important long-term growth driver.

(Photo: Zota website) Industry tailwinds—such as rising chronic disease burden, affordability pressures, and government push for generics—reinforce Zota’s positioning as a structural winner in India’s evolving pharmaceutical retail landscape.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In